Association between skeletal muscle morphometrics and overall survival among older adults with gastrointestinal cancers. Gene rearrangements/fusions identified per year.

The Australian Government is listing Retevmo® (selpercatinib) on the Pharmaceutical Benefits Scheme (PBS) for the first time ...

advanced or metastatic thyroid cancer with a RET gene fusion that can’t be treated with radioactive iodine therapy, and locally advanced or metastatic solid tumours with a RET gene fusion that ...

The US regulator says Retevmo (selpercatinib, formerly LOXO-292) can be used to treat lung and thyroid cancers with a mutation or fusion in the RET gene, specifically non-small cell lung cancer ...

Retevmo (selpercatinib) is a medicine that is used in adults for certain types of non-small-cell lung cancer (NSCLC) that have a certain fusion in a gene known as receptor tyrosine kinase (RET).

In order to discover cancer genes, Professor Hiroyuki Mano et al. developed a new screening method. At CREST in 2007, Professor Mano discovered the EML4-ALK fusion gene; at Research Acceleration in ...